IPX's P3 protocol for brilacidin OM needs to come out strong. At LEAST 300+ patients, the more the better of course.
It needs to put Galera in the dust.
Just my opinion though. And with U.S. AND EU. trials running, they can easily make that happen.
(0)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
-
-
-
-
-
-
-